IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

New Leadership Team and Appointments

Author
ivi
Date
2016-10-10 07:16
Views
3123

IVI is pleased to announce key hires and appointments. These recent additions will re-establish IVI’s executive management and scientific leadership. These individuals also bring seniority and years of experience in vaccine-related research and management to IVI, and they are instrumental in rebuilding IVI’s scientific leadership and strategic renewal.

 

Mr. Philip Driver, Deputy Director General (DDG) of Finance & Administration.
Mr. Driver oversees IVI’s finance and operations and is a member of the executive leadership team. As a finance professional with extensive global pharmaceuticals experience, Mr. Driver has served in increasingly senior finance positions during a 25 year career with GlaxoSmithKline (GSK). Most recently, he was Senior Vice President Finance and Global Lead Analytics in London, UK. Prior, he held positions as Senior Vice President Finance of Global Consumer Healthcare and spent 6 years as Finance Head of European Pharmaceuticals. He has also been responsible for finance in GSK’s Asia Pacific and Latin American operations, after commencing his pharmaceutical career with GSK in Canada. Mr. Driver was born in England and has lived in England, Canada, U.S., Mexico as well as 5 years in Asia during his career. He holds a C.P.A. from Canada and an A.C.A from U.K.

 

Dr. Jean-Louis Excler, Head of Clinical Development.
Dr. Excler leads the Clinical Development group at IVI. Dr. Excler has been a Senior Consultant, HIV Vaccine Clinical Development for the U.S. Military HIV Research Program, and since July, 2015, a consultant for IVI. Previously, he served in senior positions at the International AIDS Vaccine Initiative (IAVI), Henry M. Jackson Foundation for the U.S. Military HIV Research Program, and Pasteur Merieux Connaught (now Sanofi Pasteur). He brings more than 30 years of knowledge, expertise, and experience in vaccines and vaccination for developing countries. He was a resident doctor in Africa and supported immunization programs for children while with UNICEF. He has extensive experience in clinical strategy development and worked on the Phase III trial for the HIV vaccine in Thailand, as well as experience in regulatory affairs, particularly in India and Thailand. Dr. Excler has an M.D. with a National Doctorate of Medicine from the University of Lyon, and a Masters in Human Biology/ Parasitology.

 

Dr. Julia A. Lynch, Head of Program Management.
Dr. Lynch will head IVI’s new Program Management group, effective May 6, 2016. Prior to IVI, she served 29 years in the U.S. Army. Dr. Lynch first served as Director of the Division of Viral Diseases at the Walter Reed Army Institute of Research during which significant studies were conducted for Japanese encephalitis, adenovirus and dengue vaccines. She was appointed Director of the Military Infectious Disease Research Program at Fort Detrick, Maryland, a product development program targeting vaccines against malaria, dengue and enteric pathogens, as well as new anti-parasitic drugs and infectious disease diagnostics for resource limited settings. She later became the Science Director for the Armed Forces Research Institute of Medical Sciences in Bangkok, Thailand, where she was responsible for activities spanning eight countries in South-East Asia that included biosurveillance, basic science, pre-clinical studies and human clinical trials. Dr. Lynch received her M.D. from Columbia University and completed a Pediatric Residency and Infectious Disease fellowship at the Walter Reed Army Medical Center.

 

Dr. Viliam Pavliak, Head of Vaccine Development.
Dr. Pavliak oversees IVI’s Vaccine Development group. He was at Pfizer Worldwide Vaccine Research and Development where he was Director of the Characterization Group responsible for the characterization of subunit vaccines and the development of analytical assays for release of conjugate vaccines and intermediates. Dr. Pavliak has extensive experience and knowledge in vaccine research and development. At Wyeth Vaccine Research, he served in increasingly senior positions, becoming the Associate Director/Head of the Conjugation and Carbohydrate Chemistry Group. He worked as Principal Research Scientist at Nabi and Univax Biologics Inc., both in Rockville, Maryland, USA. Dr. Pavliak did his postdoctoral research at the National Research Council, Institute of Biological Sciences in Ottawa, Ontario, Canada and at the NIDDK-Section of Carbohydrates at the US National Institutes of Health in Bethesda, Maryland. Dr. Pavliak is a member of the Scientific Advisory Board of GlycoNet (Canadian Glycomics Network, Alberta, Canada). He has a Ph.D and M.Sc. in Biochemistry from the Slovak Technical University, Bratislava, Slovakia

 

In addition, there have been two critical appointments on the executive leadership team: Dr. Laura Digilio as Deputy Director General of Development & Delivery and Dr. In-Kyu Yoon as Deputy Director General of Science. Dr. Digilio previously served as IVI's Acting Head of Development & Delivery. As Deputy Director General of Development & Delivery, Dr. Digilio oversees IVI’s Clinical Development, Regulatory, Epidemiology, Policy & Economic Research, and Biostatistics and Data Management groups, as well as the Hepatitis E Program. Dr. Yoon joined IVI in August, 2015 as Director of the Dengue Vaccine Initiative (DVI). As Deputy Director General of Science, Dr. Yoon oversees IVI’s Clinical Research Labs, and Vaccine Development and Quality Management groups and leads DVI and our new MERS-CoV Program. For more information, please visit www.ivi.intfor their bio-sketches.

DONATE